Rekombinanter VEGF (Ranibizumab Biosimilar) Antikörper

Produktnummer ABIN7200657

Der Humanized Monoklonal anti-VEGF (Ranibizumab Biosimilar) Antikörper wird verwendet zum Nachweis von VEGF (Ranibizumab Biosimilar) in Proben von Human. Er wurde validiert für FACS und in vivo.

Kurzübersicht für Rekombinanter VEGF (Ranibizumab Biosimilar) Antikörper (ABIN7200657)

Target: VEGF (Ranibizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Fragment: Fab fragment

Reaktivität: Human

Wirt: Humanized

Klonalität: Monoklonal

Konjugat: Dieser VEGF (Ranibizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Güteklasse: Research Grade

Produktdetails anti-VEGF (Ranibizumab Biosimilar) Antikörper

Verwendungszweck: Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)

Spezifität: The Fab protein ranibizumab specifically binds to the human VEGF-A.

Produktmerkmale: The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss. Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

Aufreinigung: Protein A or G affinity column

Reinheit: >95 % by reducing SDS-PAGE

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Functional assay, neutralization.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Lagerung: 4°C,-20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu VEGF (Ranibizumab Biosimilar)

Target: VEGF (Ranibizumab Biosimilar)

Andere Bezeichnung: Ranibizumab Biosimilar

Substanzklasse: Biosimilar